Retraction notice to “Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors” [Lung Cancer 71 (2011) 283–290, (S0169500210002746), (10.1016/j.lungcan.2010.06.005)];Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

Lung Cancer

Volumn 71, Issue 3, 2011, Pages 283-290

  Morgillo, Floriana ^a   D'Aiuto, Elena ^a   Troiani, Teresa ^a   Martinelli, Erika ^a   Cascone, Tina ^a   De Palma, Raffaele ^a   Orditura, Michele ^a   De Vita, Ferdinando ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bortezomib; EGFR; Erlotinib; Gefitinib; Proteasome

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BORTEZOMIB; CASPASE 8; DEATH RECEPTOR 5; DEGUELIN; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN KINASE B; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALU 3 CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 79851516240     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2023.107226     Document Type: Erratum

References (36)

1. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 13:1160-1174.
2. Arteaga C.L. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 2003, 21. 289-91s.
3. Viloria-Petit A.M., Kerbel R.S. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004, 58:914-926.
4. Morgillo F., Bareschino M.A., Bianco R., Tortora G., Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007, 9:788-799.
5. Normanno N., Tejpar S., Morgillo F., De Luca, Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009, 6:519-527.
6. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003, 9:2316-2326.
7. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22:2818-2822.
8. Bross P.F., Kane R., Farrell A.T., Abraham S., Benson K., Brower M.E., et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004, 10:3954-3964.
9. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 2007, 12:318-326.
10. Sterz J., von Metzler I., Hahne J.C., Lamottke B., Rademacher J., Heider U., et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008, 17:879-895.
11. Kesarwala A.H., Samrakandi M.M., Piwnica-Worms D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res 2009, 3:976-983.
12. Lorch J.H., Thomas T.O., Schmoll H.J. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007, 2:727-734.
13. Codony-Servat J., Tapia M.A., Bosch M., Oliva C., Domingo-Domenech J., Mellado B., et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 3:665-675.
14. An J., Retting M.B. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effect of bortezomib. Mol Cancer Ther 2007, 6:61-69.
15. Cascone T., Morelli M.P., Morgillo F., Kim W.Y., Rodolico G., Pepe S., et al. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 2008, 216:698-707.
16. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 20:101000-101011.
17. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 10:2895-2899.
18. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006, 17:487-494.
19. Lee H.Y., Oh S.H., Woo J.K., Kim W.Y., Van Pelt C.S., Price R.E., et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005, 97:1695-1699.
20. Neri A., Marmiroli S., Tassone P. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008, 49:1374-1383.
21. Chen K.F., Yeh P.Y., Hsu C., Hsu C.H., Lu Y.S., Hsieh H.P., et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009, 284:11121-11133.
22. Fribley A., Wang C.Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006, 5:745-748.
23. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., Huang P., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005, 65:11510-11519.
24. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003, 100:9946-9951.
25. Landowski T.H., Megli C.J., Nullmeyer K.D., Lynch R.M., Dorr R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65:3828-3836.
26. Oyadomari S., Mori M. Roles of CHOP/Gdd153 in endoplasmic reticulum stress. Cell Death Differ 2004, 11:381-389.
27. McCullough K.D., Martindale J.L., Klotz L.O. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2004, 21:1249-1259.
28. Yamaguchi H., Wang H.G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 2004, 279:45495-45502.
29. Abdelrahim M., Newman K., Vanderlaag K., Samudio I., Safe S., et al. 3,3-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006, 27:717-728.
30. Horinaka M., Yoshida T., Shiraishi T., Nakata S., Wakada M., Nakanishi R., et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005, 24:7180-7189.
31. Kazhdan I., Marciniak R.A. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Cancer Gene Ther 2004, 11:691-698.
32. Jin Z., El-Deiry W.S. Overview of cell death signalling pathways. Cancer Biol Ther 2005, 4:139-163.
33. Benz E.J., Nathan D.G., Amaravadi R.K., Danial N.N. Targeting the cell death-survival equation. Clin Cancer Res 2007, 13:7250-7253.
34. Rutkowski D.T., Kaufman R.J. A trip to the ER: coping with stress. Trends Cell Biol 2004, 14:20-28.
35. Mimnaugh E.G., Xu W., Vos M., Yuan X., Isaacs J.S., Bisht K.S., et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004, 3:551-566.
36. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008, 12:1013-1030.